XORTX Hits Pause on Share Consolidation Amid Regulatory Scrutiny

CALGARY, AB – March 26, 2026 – XORTX Therapeutics Inc. has abruptly delayed a critical share consolidation plan just one day before it was scheduled to take effect, introducing a new layer of uncertainty for the clinical-stage pharmaceutical company as it races to maintain its Nasdaq listing.

The Calgary-based company, which is developing treatments for gout and progressive kidney disease, announced today that its 1-for-5 reverse stock split will now be effective on April 6, 2026, instead of the previously announced date of March 27. The company cited vague "timing considerations" for the delay, noting that the move remains contingent on receiving all necessary approvals from both the TSX Venture Exchange (TSXV) and the Nasdaq Stock Exchange.

The last-minute change throws a spotlight on the procedural and regulatory pressures facing the dual-listed company and raises questions among investors about whether the delay is a minor administrative hiccup or a signal of more significant hurdles.

A Race Against the Compliance Clock

The share consolidation is not a matter of choice for XORTX, but a strategic necessity driven by the stringent rules of the Nasdaq market. The primary goal of the corporate action is to artificially boost the company's per-share price to regain compliance with Nasdaq's minimum bid price requirement of $1.00.

Like many development-stage biotech firms, XORTX has seen its stock price fall below this critical threshold. In response, Nasdaq issued a notice, setting a firm deadline of April 13, 2026, for the company's stock to trade above $1.00 for at least ten consecutive business days. Failure to meet this requirement could result in the stock being delisted from the major U.S. exchange, a move that would severely limit its visibility, liquidity, and appeal to institutional investors.

Reverse stock splits are a common, if often unpopular, tool used by companies to solve this specific problem. By consolidating five existing shares into one new share, XORTX aims to multiply its stock price by five, theoretically lifting it well above the $1.00 minimum. Following the proposed consolidation, the company's number of outstanding common shares would shrink from nearly 7 million to approximately 1.4 million.

While the maneuver does not change the overall market value of the company, it is often viewed with skepticism by the market. Such actions are frequently interpreted as a temporary fix for a struggling stock price rather than a solution to underlying business challenges. The success of the strategy hinges on the post-split price holding its ground, which is never guaranteed.

Navigating a Dual-Listing Labyrinth

The delay shines a light on the intricate regulatory dance required for companies listed on multiple exchanges. XORTX trades on both the Nasdaq in the U.S. and the TSX Venture Exchange in Canada, meaning any major corporate action like a share consolidation must pass muster with two distinct regulatory bodies.

In its initial announcement on March 25, following shareholder approval, XORTX had indicated that the TSXV had already approved the consolidation. However, today’s press release announcing the delay stated that the plan "remains subject to the receipt of all required approvals" from both the TSXV and Nasdaq. This subtle shift in language suggests that the path to final approval may not have been as clear as previously implied.

Delays in these processes can arise for numerous reasons. Regulators may request additional information, filings could be deemed incomplete, or the exchanges might simply have administrative backlogs. For a dual-listed entity, the need to coordinate filings, timelines, and communications between two separate jurisdictions adds significant complexity. The "timing considerations" cited by XORTX likely fall within this complex procedural landscape.

This diligence is particularly important in the context of the looming Nasdaq deadline. With the new effective date pushed to April 6, XORTX has a much tighter window to achieve the required ten consecutive days of trading above $1.00 before the April 13 cutoff. Any further delays could jeopardize the entire effort.

What the Delay Means for a Clinical-Stage Company

For a company like XORTX, whose value is tied to the long-term promise of its drug pipeline, maintaining a stable presence on a major exchange like Nasdaq is paramount. It is not merely a matter of prestige; it is a critical component of its financial strategy. A Nasdaq listing provides the access to capital necessary to fund costly and lengthy clinical trials.

XORTX is advancing a portfolio of therapies aimed at significant unmet medical needs, including its lead program for gout (XRx-026) and a treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD), a serious genetic disorder. It is also developing therapies for acute kidney injury and diabetic nephropathy. These ambitious programs require substantial and sustained investment, which is far easier to secure when a company's shares are liquid and accessible to a broad base of U.S. and international investors.

Delisting would relegate the stock to over-the-counter (OTC) markets, which are often perceived as riskier and are avoided by many large investment funds. This would not only make it harder to raise future capital but could also negatively impact the company's ability to attract strategic partners or talent.

Therefore, the share consolidation, and its smooth execution, is more than just a financial housekeeping task. It is a foundational move to secure the company's financial footing as it works to bring its innovative therapies closer to the market. The unexpected delay, while potentially minor, adds a degree of unwelcome drama to this crucial process. Investors will now be watching closely to see if the company can navigate these final hurdles and execute its plan by the new April 6 target, ensuring its focus can return from stock market mechanics to advancing its promising medical science.